EMA + CEP: Reconciling EU Generic Export Realisation

An Indian Tier-1 pharma formulator running EU-CEP-certified formulation plants at Goa and Kurkumbh — the two sites that carry the European Directorate for the Quality of Medicines Certificate of Suitability status that permits the export of finished dosage forms into the European Union market — closes November 2025 with an EU-shipment ledger that spans the United Kingdom, Germany, France, Italy, the Netherlands and the Nordics. Roughly 35 percent of the illustrative Rs 3,200 crore annual EU-market formulation export turnover flows to the United Kingdom (still a distinct regulatory market post-Brexit but shipped under a very similar operating discipline), 25 percent to Germany, 15 percent each to France and Italy, and the balance across the Netherlands and the Nordic markets. Each per-shipment record has to reconcile the shipping bill on ICEGATE, the FCA-Nhava Sheva commercial invoice, the EUR or GBP e-BRC realisation from the AD Bank, the Advance Authorisation SION consumption debit, the RoDTEP scrip issuance at the Appendix 4R Chapter 30 rate, the Section 54(3) LUT refund attribution, and the Ind AS 21 forex-translation tracker across the invoice-date, month-end closing-date and settlement-date rates. That is EMA CEP EU generic pharma export reconciliation India at operating scale, and the discipline that separates a defensible monthly close from a scramble at year-end is a per-shipment record keyed on the shipping bill number that ties every downstream reconciliation surface back to the single container that left Nhava Sheva.

The reconciliation in one paragraph

An Indian pharma exporter selling into the European Union runs a set of parallel regulatory and financial reconciliation surfaces that all key on the same per-shipment event. The EMA (European Medicines Agency) marketing authorisation for each finished product sits alongside the EDQM CEP for each active pharmaceutical ingredient — both are prerequisites to place the medicinal product on the EU market. INCOTERMS 2020 governs the commercial-invoice valuation: FCA-INCOTERM at Nhava Sheva Container Terminal is the preferred rule for most Indian pharma EU export shipments because risk transfers to the buyer at the container gate and the commercial-invoice value is the FOB Nhava Sheva base. Foreign exchange realisation is invoiced in EUR or GBP; the per-shipment e-BRC (Electronic Bank Realisation Certificate) issued by the AD Bank ties to the shipping bill by the Bill of Lading number. RoDTEP Chapter 30 rebate at the Appendix 4R rate is issued as a transferable e-scrip on ICEGATE. Advance Authorisation duty-free imports of APIs are mapped per-shipment against the SION consumption. Section 54(3) refund of accumulated unutilised input tax credit on zero-rated exports is filed monthly on Form GST RFD-01 with Statement 3, against the Letter of Undertaking route (Form GST RFD-11). Ind AS 21 governs the forex translation at initial recognition, at each intervening reporting date, and at settlement. The EDQM CEP annual maintenance fee — of the order of EUR 1,200 to 1,500 per API — and the EMA variation dossier fees are recurring regulatory costs loaded against the export margin. Every surface must reconcile back to the per-shipment record so the monthly close and the annual EODC filing hold.

What the scenario looks like in India — safe illustrative brand persona

The Indian pharma industry’s EU-market export footprint is anchored by a handful of Tier-1 integrated formulators whose formulation plants have secured EU-CEP status. Cipla’s Goa and Kurkumbh formulation plants carry EU-CEP certification and support the group’s EU-market generic formulations business. Sun Pharmaceutical Industries, Dr Reddy’s Laboratories, Aurobindo Pharma, Lupin, Zydus Lifesciences and Glenmark Pharmaceuticals operate parallel EU-CEP-certified sites across their multi-plant networks. Tier-2 formulators including Ipca Laboratories, Ajanta Pharma and Torrent Pharmaceuticals hold EU-market positions in specific therapeutic categories. The specialty pipeline is anchored by Biocon Biologics on biosimilars and by Divi’s Laboratories on API supply to EU-market formulators. Each plant’s EU-export flow runs through Nhava Sheva Container Terminal as the primary west-coast port — the JNPT complex in Navi Mumbai — with occasional flows via Mundra for northern manufacturing sites.

For the reconciliation this article walks through, the reference persona is a Tier-1 integrated formulator whose Goa and Kurkumbh formulation plants are EU-CEP-certified, at an illustrative annual EU-market formulation export turnover of the order of Rs 3,200 crore. The market split runs approximately 35 percent United Kingdom, 25 percent Germany, 15 percent France, 15 percent Italy, with the balance flowing across the Netherlands and the Nordic markets. The commercial invoicing convention across the network is FCA-INCOTERM 2020 at Nhava Sheva Container Terminal, with the risk transfer to the EU buyer at the container gate and the commercial-invoice value equal to the FOB Nhava Sheva base. Foreign exchange realisation is split between EUR-invoiced flows to the eurozone destinations and GBP-invoiced flows to the United Kingdom. The finance team’s monthly export-close discipline is a per-shipment record that ties every downstream reconciliation surface back to the shipping bill number that ICEGATE issues when the container leaves Nhava Sheva.

The regulatory overlay — Section 54(3), FTP 2023, Ind AS 21, and the EMA-EDQM stack

Five regulatory anchors govern the Indian pharma EU-export reconciliation cycle: two Indian tax anchors, one Indian foreign-trade anchor, one Indian accounting anchor, and one EU regulatory anchor.

Section 54(3) of the Central Goods and Services Tax Act 2017 read with Rule 96A of the CGST Rules 2017 permits an exporter to make zero-rated exports without payment of integrated tax under a Letter of Undertaking (LUT) filed in Form GST RFD-11, and to claim refund of accumulated unutilised input tax credit under Section 54(3). The refund is filed monthly on Form GST RFD-01 with Statement 3 for zero-rated exports (parallel to the Statement 1A that supports the domestic Rule 89(5) inverted-duty refund pharma formulations claim). Both routes can operate in the same tax period at the same GSTIN provided the input attribution splits cleanly between domestic inverted-rated supplies and zero-rated export supplies.

The Foreign Trade Policy 2023 governs two adjacent export incentive mechanics. RoDTEP (Remission of Duties and Taxes on Exported Products) is a rate-based rebate of embedded taxes and levies not otherwise refunded on exported products, notified per HSN heading in Appendix 4R. Chapter 30 pharma formulations sit in the 1.2 to 1.8 percent of FOB range depending on the specific HSN sub-heading; the rebate is issued as a transferable e-scrip credited to the exporter’s ledger on ICEGATE. The Advance Authorisation Scheme permits duty-free import of inputs physically incorporated into the exported product, subject to the Standard Input-Output Norms (SION) notified per HSN and per product; per-shipment consumption is debited against the authorisation and the annual Export Obligation Discharge Certificate (EODC) closes the authorisation once the export obligation is fulfilled. The pharma export drawback + RoDTEP reconciliation for formulations walkthrough covers the RoDTEP and drawback mechanic in more granular detail.

Ind AS 21 (The Effects of Changes in Foreign Exchange Rates) governs the accounting translation of the EU-invoiced trade receivable. Paragraph 21 requires initial recognition at the spot exchange rate on the date of the transaction — the shipping-bill or export-invoice date. Paragraph 23 requires monetary items to be translated at the closing rate at each reporting date — every intervening month-end before realisation. Paragraph 28 requires exchange differences on settlement to be recognised in profit or loss in the period in which they arise — the e-BRC realisation date at the AD Bank settlement rate. The per-shipment forex tracker rolls to the monthly Ind AS 21 forex-variance disclosure.

The EU regulatory anchor is the twin stack of the EMA marketing authorisation (for the finished product) and the EDQM Certificate of Suitability (for each API). The EMA marketing authorisation authorises the specific formulation, dose, indication and label to be placed on the EU market; it carries no renewal fee post the 2018 EU legislative reform, but variation dossier fees (Type IA, Type IB, Type II changes) apply when the exporter changes manufacturing sites, specifications or labelling. The EDQM CEP is granted per API and confirms that the substance meets the relevant European Pharmacopoeia monograph; annual maintenance fees apply per CEP in the order of EUR 1,200 to 1,500, and renewal is required every five years. Both cost streams are loaded against the specific product SKUs they support in the monthly export-margin bridge.

A worked example — a per-shipment reconciliation record

Illustrative — the following per-shipment reconciliation record represents the operating pattern of a Tier-1 pharma EU-market exporter. Cross-verify against your own shipping bill, e-BRC and Advance Authorisation ledgers before action.

Consider a single shipment that clears Nhava Sheva on 10 October 2025 destined for Rotterdam and onward road delivery to a German generic distributor. The commercial invoice value at FCA-Nhava Sheva is EUR 1,850,000 covering approximately 4.2 million tablets of a Chapter 30 heading 3004 finished-formulation SKU. The EUR/INR spot rate on 10 October 2025 is illustratively 95.20, giving an initial-recognition trade receivable of Rs 176.12 crore.

The per-shipment reconciliation surfaces:

The e-BRC issued by the AD Bank ties the realisation record back to the shipping bill by the Bill of Lading number. If the realisation runs short of the shipping-bill FOB value beyond the RBI-prescribed variance tolerance, the DGFT and RBI reporting flags the shortfall for follow-up. The forex variance of Rs 2.04 crore across the three-month cycle hits the January 2026 P&L per Ind AS 21 paragraph 28.

Rolled to the annual bridge at Rs 3,200 crore illustrative EU-market export turnover, the RoDTEP scrip issuance at an illustrative 1.5 percent Chapter 30 rate produces Rs 48 crore of transferable scrip credit annually. The Section 54(3) LUT refund runs against the aggregate Net ITC attributable to the export leg — a substantial monthly refund flow that is filed on Form GST RFD-01 alongside the domestic Rule 89(5) claim. The EDQM CEP annual maintenance fee load across an illustrative product portfolio of 30 to 40 distinct API-formulation combinations sits at EUR 40,000 to 60,000 per year (roughly Rs 40 to 60 lakh at illustrative EUR/INR rates) — a small absolute number against the Rs 3,200 crore turnover, but a fixed regulatory cost that finance teams track as a specific line in the export-margin bridge.

Common reconciliation breakages

Five breakages recur across Indian pharma EU-market exporters running the per-shipment reconciliation cycle:

• Shipping bill to commercial invoice FOB mismatch. The shipping bill FOB-INR value at customs and the commercial invoice value at FCA-Nhava Sheva must reconcile through the shipping-bill-date exchange rate published by CBIC. When the operations team files the shipping bill on a different date to the commercial invoice issuance, the two FOB-INR values diverge, and the downstream Section 54(3) LUT refund attribution loses its per-shipment integrity. Reconciliation discipline: the shipping-bill date, the commercial invoice date and the CBIC exchange rate reference are locked to the per-shipment record at container-gate crossing.

• e-BRC to shipping bill mismatch by BL number. The e-BRC issued by the AD Bank ties to the shipping bill by the Bill of Lading number — the primary reconciliation key. When the AD Bank feeds an e-BRC with a truncated or mis-punched BL number, the automated match to the shipping bill fails, and the shipment shows as an outstanding receivable in the export-ledger ageing bucket even though realisation has occurred. Reconciliation discipline: a BL-number normalisation routine that strips whitespace, standardises the liner-code prefix and cross-checks against the shipping-bill BL field before the AD Bank feed is committed to the export-ledger.

• Advance Authorisation SION consumption drift. Per-shipment SION consumption is debited against the Advance Authorisation ledger; the annual EODC filing closes the authorisation. When per-shipment consumption is booked at a batch rate that drifts from the SION norm (for example, when the manufacturing yield changes and the actual API consumption per unit finished formulation moves), the Advance Authorisation ledger and the shipping-bill trail diverge, and the EODC filing runs into shortfall or excess reconciliations at year-end. Reconciliation discipline: a rolling per-shipment SION-consumption reconciliation feeds a monthly variance alert against the Advance Authorisation ledger balance.

• RoDTEP scrip issuance timing versus export invoice recognition. RoDTEP scrip is credited to the ICEGATE ledger with a lag from the shipping bill date. The revenue recognition point for the export sale under Ind AS 115 is typically the shipping-bill date (control transfers when the goods are handed to the carrier under FCA), but the RoDTEP scrip issuance recognition timing depends on the accounting policy — cash-basis on scrip receipt or accrual-basis on export completion. The finance team’s policy choice locks the treatment; the reconciliation must reflect it consistently across the year.

• Ind AS 21 forex tracker desynchronisation. The three-touchpoint forex tracker (initial recognition, month-end translation, settlement) requires the exact EUR/INR rate at each touchpoint. When the finance team uses a period-average rate rather than the spot rate at each specific date, the aggregate forex variance is understated and the P&L disclosure per paragraph 28 is misstated. Reconciliation discipline: per-shipment date-specific spot rate capture from a reliable feed (RBI reference rate or a specified market-rate publisher), applied consistently across the initial recognition, monthly closing and settlement translations.

How a reconciliation platform handles this

A purpose-built pharma reconciliation platform ingests the ICEGATE shipping bill feed, the AD Bank e-BRC feed, the Advance Authorisation ledger, the RoDTEP scrip issuance record and the plant’s own ERP export-sale posting — and produces a per-shipment reconciliation record keyed on the shipping bill number that ties every downstream surface (commercial invoice FOB, EUR or GBP realisation, SION consumption, RoDTEP scrip, Section 54(3) LUT refund attribution, Ind AS 21 forex variance) back to the single container that left Nhava Sheva. The platform normalises BL numbers across the AD Bank feed, holds the per-shipment forex tracker across initial recognition, monthly closing and settlement rates, and rolls the aggregate to the monthly export-margin bridge with EDQM CEP annual maintenance fees and EMA variation dossier fees loaded against the specific product SKUs. Match rate improvement of 51 to 88 percent on the per-shipment e-BRC to shipping bill reconciliation, combined with an ISO 27001:2022 posture and DPDP Act 2023 aligned data handling, is what makes the platform an operating investment for a Tier-1 pharma EU-market exporter running a multi-country per-shipment export flow.

Cross-cluster bridges and where to read next

This EU-export reconciliation sits alongside the ANDA US generic export revenue recognition milestone reconciliation cornerstone that covers the parallel US-market export flow with the Section 505(j) FDCA milestone framework (tentative approval, final approval, 180-day exclusivity). The emerging markets Africa LatAm generic pharma export reconciliation walkthrough covers the WHO PQ, NAFDAC, SAHPRA, ANVISA and COFEPRIS regulatory stack for the emerging-market export flows. The pharma export drawback + RoDTEP reconciliation for formulations walkthrough covers the Appendix 4R rate schedule and drawback mechanic in more detail.

The domestic-refund parallel to the Section 54(3) LUT export refund is the Rule 89(5) inverted duty refund pharma formulations cornerstone, which covers the Chapter 30 domestic 5 percent inverted-duty cycle. The API-versus-formulation HSN mechanic that underlies the Advance Authorisation SION mapping sits in the API vs formulation HSN 2941 3003 3004 reconciliation guide. The methodology framework for building the per-shipment reconciliation record sits in Terra Insight’s reconciliation failure mode analysis pillar and the reconciliation playbook for monthly close operations pillar. The human-error surface across the per-shipment record is documented in the human errors detection envelope anchor. The commercial pillar for the pharma sub-cluster is Pharma reconciliation software India; the broader authority for the platform is reconciliation software India with the specialised GST reconciliation software surface for the Section 54(3) refund workflow. The pharma cluster hub is the entry point for the full 45-article programme.

The five FAQs below address the operational questions Indian pharma export controllers and indirect-tax leads ask most often when building a per-shipment EU-market export reconciliation.

Terra Insight Editorial Team Reconciliation Infrastructure

Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →

Published 17 July 2026

Domain expertise

TDS Reconciliation GST Input Credit Platform Settlements NACH Batch Matching Bank Reconciliation Form 26AS Matching ERP Integrations Enterprise Finance Ops

Reviewed by

NK

Navin Krishnan

Managing Director & Founder — Terra Insight

Ex Amazon India · Intuit QuickBooks · Tata nexarc

ISO 27001:2022 Patent Pending Incorporated 2024